Good to hear from you dwbodwb2!
This deal will add 11 million dollars over the last two quarters of the fiscal year. That is a BIG bump.
I'm curious if the company will approach break even over that time period.
Over the life of the deal, if GSK has a blockbuster drug, CDXS will do very well.
Ignore all the chatter on the board. They will all move on to the next target in a day or two.
Curious if any mutual funds have been buying or is it all just day traders.
This will be a crazy day. I have no idea where the share price will land.
The really good thing about this deal is not just the new revenue. It is the fact that their new business model has been vindicated. They have cut expenses very well. Now we have new revenue. Longs have been rewarded.
This is like landing a big recruit in college sports. Now other pharma companies will take notice and other deals will follow.
Very positive news. Any potential need for cash has just been postponed for another year or more. No dilution anytime soon.
CDXS is dead money right now. Despite all my planning, I didn’t anticipate the daily volume dropping so low. It is very difficult to trade in or out.
The cash burn is great--very low. They are set on cash for a long time. My basic view of the company is still positive, however, they didn’t release one piece of positive PR the entire second quarter. This is a slow process.
Right now it is totally news driven. A piece of good news and it’s off to the races. When that happens is anybody’s guess. Could be 6 months or more.
The success of the new business plan remains to be seen.
No revisions in the outlook. Not a lot of new info. A sense of optimism(maybe).
The cash burn was remarkably low. I was predicting 3 million! It seems they are comfortable with their business plan. So far so good!
The stock price has dropped on very low volume recently. I am hoping that a couple of mutual funds will be buyers after the earnings report. It would take only a hundred thousand share volume for the price to move upward significantly higher.